We are live on ! Find out more
LBA

Letko, Brosseau & Associates Portfolio holdings

AUM $6.77B
1-Year Est. Return 38.11%
This Fund
S&P 500
This Quarter Est. Return
+10.66%
1 Year Est. Return
+38.11%
3 Year Est. Return
+83.35%
5 Year Est. Return
+109.01%
10 Year Est. Return
+317.99%
AUM
$5.49B
AUM Growth
+$387M
Cap. Flow
-$101M
Cap. Flow %
-1.83%
Top 10 Hldgs %
34.03%
Holding
100
New
2
Increased
18
Reduced
60
Closed
4

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$28.4M
2
MRNA icon
Moderna
MRNA
+$26.9M
3
OTEX icon
Open Text
OTEX
+$11.4M
4
CAE icon
CAE Inc
CAE
+$8.93M
5
BNS icon
Scotiabank
BNS
+$7.52M

Sector Composition

Rank Sector Weight
1 Financials 31.47%
2 Communication Services 16.33%
3 Materials 11.56%
4 Energy 9.5%
5 Healthcare 9.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
C icon
26
Citigroup
C
$228B
$80.9M 1.47%
1,572,678
-32,247
-2% -$1.43M
EMN icon
27
Eastman Chemical
EMN
$7.53B
$77M 1.4%
857,119
+87,845
+11% +$7M
GILD icon
28
Gilead Sciences
GILD
$181B
$76.7M 1.4%
947,128
-23,787
-2% -$1.85M
CAE icon
29
CAE Inc
CAE
$7.63B
$76.1M 1.39%
3,508,379
+418,775
+14% +$8.93M
SWKS icon
30
Skyworks Solutions
SWKS
$13.5B
$74.2M 1.35%
660,048
-2,809
-0.4% -$275K
STT icon
31
State Street
STT
$50.9B
$69.4M 1.26%
895,641
-18,074
-2% -$1.26M
BERY
32
DELISTED
Berry Global Group, Inc.
BERY
$62.8M 1.14%
1,014,839
-25,984
-2% -$1.47M
TFC icon
33
Truist Financial
TFC
$61.6B
$61.8M 1.13%
1,673,201
-8,055
-0.5% -$253K
CVS icon
34
CVS Health
CVS
$121B
$60.1M 1.09%
760,840
-10,270
-1% -$731K
VZ icon
35
Verizon
VZ
$214B
$59M 1.07%
1,563,706
-20,199
-1% -$715K
SHEL icon
36
Shell
SHEL
$283B
$58.7M 1.07%
891,772
-31,660
-3% -$2.08M
T icon
37
AT&T
T
$183B
$57.8M 1.05%
3,446,730
-899,852
-21% -$14.2M
ELP
38
DELISTED
Companhia Paranaense de Energia (COPEL)
ELP
$56.4M 1.03%
5,460,545
-1,471,949
-21% -$10.7M
WMT icon
39
Walmart Inc
WMT
$858B
$55.9M 1.02%
1,064,550
-64,905
-6% -$3.43M
WFC icon
40
Wells Fargo
WFC
$271B
$53.6M 0.98%
1,088,059
-19,440
-2% -$839K
ABBV icon
41
AbbVie
ABBV
$465B
$52M 0.95%
335,634
-5,110
-1% -$745K
COP icon
42
ConocoPhillips
COP
$170B
$51.3M 0.93%
442,064
-12,341
-3% -$1.44M
CRUS icon
43
Cirrus Logic
CRUS
$6.12B
$50.2M 0.91%
603,734
-10,640
-2% -$797K
MAC icon
44
Macerich
MAC
$6.35B
$47.9M 0.87%
3,106,715
-420,800
-12% -$5.01M
SKX
45
DELISTED
Skechers
SKX
$47.5M 0.87%
762,630
-28,925
-4% -$1.56M
BAC icon
46
Bank of America
BAC
$416B
$45.7M 0.83%
1,358,068
-24,335
-2% -$709K
SBS icon
47
Sabesp
SBS
$18.4B
$45.5M 0.83%
15,410,216
-257,439
-2% -$654K
GSK icon
48
GSK
GSK
$100B
$43.7M 0.8%
1,179,935
-18,033
-2% -$647K
QSR icon
49
Restaurant Brands International
QSR
$26.3B
$43M 0.78%
547,649
-60,650
-10% -$4.22M
ORCL icon
50
Oracle
ORCL
$404B
$42.6M 0.78%
403,702
-16,435
-4% -$1.79M

Similar funds

Letko, Brosseau & Associates's Q4 2023 Portfolio in Review

As of Q4 2023, Letko, Brosseau & Associates held 100 positions worth $5.49B, up 7.6% from $5.1B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Letko, Brosseau & Associates's Q4 2023 filing shows 2 new, 18 increased, 60 reduced and 4 closed positions. Its largest new stake was Moderna: 319,430 shares worth $31.8M. The largest sale was Celestica, an estimated $31.6M.

By sector, the portfolio is most concentrated in Financials at 31% of assets, up from 30% a quarter earlier, followed by Communication Services and Materials.

  • Letko, Brosseau & Associates's largest Q4 2023 buy was Moderna: 319,430 shares worth $31.8M.
  • Letko, Brosseau & Associates added most to Pfizer in Q4 2023, an estimated $28.4M increase.
  • Letko, Brosseau & Associates's biggest Q4 2023 reduction was Celestica, cutting an estimated $31.6M.
  • Letko, Brosseau & Associates fully exited Spirit Airlines, Inc. in Q4 2023, selling an estimated $27.2M.
  • Letko, Brosseau & Associates's ten largest holdings make up 34% of its $5.49B portfolio in Q4 2023.
  • Letko, Brosseau & Associates opened 2 new positions and closed 4 in Q4 2023.
  • Letko, Brosseau & Associates's portfolio value rose 7.6% quarter-over-quarter to $5.49B.

Based on Letko, Brosseau & Associates's 13F filing for Q4 2023, filed 12 Feb 2024.